Orsense - Non-Invasive Technologues

Please choose your location:

   
  •  
  •  
  •  
  •  
  •  
Latest News

May. 14, 2019
FDA Grants Market Clearance for the OrSense NBM200; the First Noninvasive Hemoglobin System Cleared for Use in Blood Donation Centers

Oct. 13-16, 2018
Meet us at the upcoming AABB annual meeting in Boston, on October 13-16, 2018- Booth #2824

Jun. 2-6, 2018
Meet us at the 35th International Congress of ISBT - Booth #1806

Aug. 5, 2015
OrSense re-awarded the Catalan blood bank contract for pre-donation Hemoglobin testing

Oct. 28, 2014
OrSense delivers first systems in Mexico

Oct. 14, 2014
CSL Plasma selects OrSense NBM200 Non-invasive Hemoglobin testing device

Jul. 15, 2014
NBM200 receives Anvisa clearance Orsense delivers first systems in Brazil

May. 31, 2014
Haema AG replaces capillary testing with OrSense NBM200 Non-invasive Hemoglobin testing device

Nov. 5, 2013
OrSense Receives FDA Clearance for its Noninvasive Hemoglobin Monitor

Oct. 28, 2013
OrSense Non Invasive Hemoglobin Monitor Received CFDA Approval for Marketing in China

Welcome

OrSense is a medical device company that develops and commercializes innovative non-invasive monitoring technologies for continuous and spot measurements of blood parameters.

Our products are based on our revolutionary, proprietary SpectOLightTM Occlusion Spectroscopy technology, enabling easy and accurate measurements of blood parameters under extreme conditions by overcoming key obstacles that hinder the performance of competing technologies. Our current focus is non-invasive hemoglobin testing for the detection of anemia in diverse clinical settings.

Get the Latest
Clinical Data
Booklet